País: Regne Unit
Idioma: anglès
Font: MHRA (Medicines & Healthcare Products Regulatory Agency)
Aspirin
Actavis UK Ltd
B01AC06
Aspirin
75mg
Gastro-resistant tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02090000; GTIN: 5012617012425 5012617012340
1 Actavis Logo PACKAGE LEAFLET: INFORMATION FOR THE USER ASPIRIN 75MG GASTRO-RESISTANT TABLETS acetylsalicylic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - The full name of this medicine is Aspirin 75mg Gastro-resistant Tablets but within the leaflet it will be referred to as Aspirin tablets. WHAT IS IN THIS LEAFLET : 1. What Aspirin tablets are and what they are used for 2. What you need to know before you take Aspirin tablets. 3. How to take Aspirin tablets. 4. Possible side effects 5. How to store Aspirin tablets. 6. Contents of the pack and other information 1. WHAT ASPIRIN TABLETS ARE AND WHAT THEY ARE USED FOR Aspirin tablets contain acetylsalicylic acid, which in low doses belong to a group of medicines called anti- platelet agents. Platelets are tiny cells in the blood that cause the blood to clot and are involved in thrombosis. When a blood clot occurs in an artery it stops the blood flowing and cuts off the oxygen supply. When this happens in the heart it can cause a heart attack or angina; in the brain it can cause a stroke. Aspirin tablets are taken to reduce the risk of blood clots forming and thereby prevent further: - heart attacks - strokes - cardiovascular problems in patients who suffer from stable or unstable angina (a type of chest pain). Aspirin tablets are also used to prevent the formation of blood clots after certain types of heart surgery in order to widen or to unblock the blood vessels. This medicinal product is not recommended for emergencies. It can only be used as a preventive treatment. Llegiu el document complet
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Aspirin 75mg Gastro-resistant Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each gastro-resistant tablet contains 75mg acetylsalicylic acid. Excipient with known effect Each gastro resistant tablet contains 0.0016 mg sodium (Essentially ‘sodium-free’). For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gastro-resistant tablet. 75 mg: Oval, white, biconvex film-coated tablets, 9.2 x 5.2 mm. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS • Secondary prevention of myocardial infarction. • Prevention of cardiovascular morbidity in patients suffering from stable angina pectoris. • History of unstable angina pectoris, except during the acute phase. • Prevention of graft occlusion after Coronary Artery Bypass Grafting (CABG). • Coronary angioplasty, except during the acute phase. • Secondary prevention of transient ischaemic attacks (TIA) and ischaemic cerebrovascular accidents (CVA), provided intracerebral haemorrhages have been ruled out. Aspirin 75mg Gastro-resistant Tablets is not recommended in emergency situations. It is restricted to secondary prevention with chronic treatment. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults _Secondary prevention of myocardial infarction: _ The recommended dose is 75-160 mg once daily. _Prevention of cardiovascular morbidity in patients suffering from stable angina _ _pectoris: _ The recommended dose is 75-160 mg once daily. _History of unstable angina pectoris, except during the acute phase: _ The recommended dose is 75-160 mg once daily. _Prevention of graft occlusion after Coronary Artery Bypass Grafting (CABG): _ The recommended dose is 75-160 mg once daily. _Coronary angioplasty, except during the acute phase: _ The recommended dose is 75-160 mg once daily. _Secondary _ _prevention _ _of _ _transient _ _ischaemic _ _attacks _ _(TIA) _ _and _ _ischaemic _ _cerebrovascular accidents (CVA), provided intracerebral haemorrhages have been _ _ruled out: _ The recommende Llegiu el document complet